Navigation Links
ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
Date:7/29/2010

In the ongoing Phase II study, approximately 90 treatment-naive genotype 1 HCV patients have received ANA598 or placebo in combination with Pegasys® (peginterferon alfa-2a) and Copegus® (ribavirin, USP) for 12 weeks at dose levels of 200 mg bid or 400 mg bid, each with a loading dose of 800 mg bid on day one.  After week 12, patients are to continue receiving SOC.  Patients who achieved undetectable levels of virus at weeks 4 and 12 were randomized to stop all treatment at week 24 or 48.  The primary endpoint of the study is the proportion of patients who achieve undetectable levels of virus at week 12 (defined as complete Early Virological Response, or cEVR).  Additional endpoints include safety and tolerability as well as the proportion of patients with undetectable levels of virus at week 4 (defined as Rapid Virological Response, or RVR).  Patients will be followed for 24 weeks after stopping therapy to determine the rate of Sustained Virological Response, or SVR.  Approximately 90 patients have been enrolled in this study – with approximately 30 patients receiving ANA598 plus SOC at each dose level and 30 patients receiving placebo plus SOC.  The study is being managed by the Duke Clinical Research Institute (DCRI) and is being conducted at a number of clinical sites in the United States.  

About ANA598

ANA598, a direct-acting antiviral or DAA, is a non-nucleoside inhibitor of the HCV RNA polymerase and is wholly owned by Anadys.  In an ongoing Phase II study in which HCV patients received ANA598 at 200 mg bid or 400 mg bid in combination with interferon and ribavirin for twelve weeks, both dose levels showed comparable cEVR rates of 73-75% and a favorable safety profile.  In a previous Phase I study,
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
11. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 In conjunction with DURECT Corporation,s ... results press release, you are invited to listen to ... the internet on Thursday, August 7, 2014 at 4:30 ... A live audio webcast of the presentation will be ... and clicking "Investor Relations."  If you are unable to ...
(Date:7/30/2014)... , July 30, 2014 PuraMed BioScience ... marketer of over-the-counter (OTC) medicinal and healthcare products, ... M name along with the name,s red ... with the trademarked name MigraPure ®  going ... of PuraMed,s homeopathic, natural migraine pain reliever will ...
(Date:7/30/2014)... /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... announced today that they have received CE Mark ... Velox CD™ provides a safe and predictable means ... The single size velox CD™ is indicated for ... to 8F.  Velox CD™ utilizes patented ...
Breaking Medicine Technology:DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2
(Date:7/30/2014)... July 31, 2014 “United States Orthopedic Braces ... on the United States Orthopedic Braces and Supports market. The ... (in units) and average price data (in US dollars), within ... , Ankle Braces and Supports , ... and Supports. , Orthotics is a specialty within ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Nationally recognized ... CNE, ANEF, who since September 2013 has served as ... became the new dean of the College of Nursing ... move marries her leadership of the NLN, as the ... the top-ranked academic nursing and research institutions in the ...
(Date:7/30/2014)... 2014 New changes are in store for ... move to a new facility. The official date of the ... moving soon. , MedX Pharmacy will be moving into a ... 77581. This is the old Wells Fargo building. The new ... include a drive thru for convenient drop-off and pick-up of ...
(Date:7/30/2014)... Serial entrepreneur, Paul Mata, spent the early part ... most people, in 2008 he suffered extreme financial hardship and ... Paul carefully studied the difference between people who have sustainable ... on the knowledge he acquired, he was able to use ... health, but also grow his clients' personal and financial assets ...
(Date:7/30/2014)... revitalized and expanded through a U.S.-funded effort that ... access and providing cutting-edge skills labs and other ... by participants of the $130 million Medical Education ... progress being made at the African institutions. Their ... by the journal Academic Medicine . Begun ...
Breaking Medicine News(10 mins):Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 3Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 4Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 2Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 3Health News:MedX Pharmacy Relocates to New Facility 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3
... at 6th International Stem Cell Symposium Seoul, Korea - ... ... AlphaMed Press,publisher of the peer-reviewed journal STEM CELLS(R), announces that the,annual ... will be presented on June 20, 2008 in,Seoul, Korea. The US$10,000 award ...
... need, but sickest still going without, study finds , , TUESDAY, ... has resulted in some improvements for seniors but no real ... finds that Medicare beneficiaries are less likely to forego basic ... sickest patients are still skipping meds due to burdensome costs. ...
... winners from Indiana, South Carolina and Illinois are Runners-Up, ... a business niche when a friend had trouble finding ... the Year for turning his,idea into a multi-million dollar ... at the U.S. Small Business,Administration,s celebration of National Small ...
... for Policymakers, Consumers and the Media is First ... and Consumer Product,Issues, WASHINGTON, April 22 ... A Guide for,Consumers, Policymakers and the Media, the ... to provide current and scientifically accurate,information and resources ...
... greatest week after meds begin , , TUESDAY, April 22 ... are 60 percent more likely to develop pneumonia in the ... new study shows. , The risk is greatest during the ... decreases, say Dutch researchers. , "The risk of developing pneumonia ...
... Ensign,Group, Inc. (Nasdaq: ENSG ), the parent ... care services and assisted living,companies, announced today that ... results following the market close on Wednesday, May ... Conference Call, Ensign invites current and prospective ...
Cached Medicine News:Health News:Stem Cells(R) and International Stem Cell Symposium Present Annual Stem Cells(R) Young Investigator Award 2Health News:Medicare Prescription Drug Benefit Shows Mixed Results 2Health News:Medicare Prescription Drug Benefit Shows Mixed Results 3Health News:Online Job Search Company from Virginia is National Small Business of the Year 2Health News:Online Job Search Company from Virginia is National Small Business of the Year 3Health News:Online Job Search Company from Virginia is National Small Business of the Year 4Health News:Grocery Manufacturers Association Releases Science Policy Paper on Bisphenol A 2Health News:Antipsychotic Drugs Linked to Pneumonia in Elderly 2Health News:The Ensign Group Schedules 2008 First Quarter Earnings Call for Thursday, May 8, 2008 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: